Drugs Made In America Acquisition Corp Units
DMAAU
2 hedge funds and large institutions have $122K invested in Drugs Made In America Acquisition Corp Units in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
1% more capital invested
Capital invested by funds: $121K → $122K (+$1.36K)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$54 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$43 |
Top Sellers
DMAAU Hedge Fund Activity: Q2 2026 in Review
2 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Units (DMAAU) for Q2 2026, worth a combined $122K — up 1.1% from $121K a quarter earlier.
Fund positioning in DMAAU was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Clear Street, adding an estimated $54.
- 2 institutional investors held Drugs Made In America Acquisition Corp Units (DMAAU) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $122K of Drugs Made In America Acquisition Corp Units stock for Q2 2026, up 1.1% quarter-over-quarter.
- 0 funds opened new Drugs Made In America Acquisition Corp Units positions in Q2 2026 and 0 closed out.
- The largest Drugs Made In America Acquisition Corp Units buyer in Q2 2026 was Clear Street, an estimated $54 added.
Based on aggregated 13F filings for Q2 2026.